Cascadian Therapeutics, Inc.
CASC
CASC was delisted on the 8th of March, 2018.
74 hedge funds and large institutions have $110M invested in Cascadian Therapeutics, Inc. in 2014 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 22 increasing their positions, 19 reducing their positions, and 7 closing their positions.
214% more call options, than puts
Call options by funds: $2.27M | Put options by funds: $722K
114% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 7
89% more capital invested
Capital invested by funds: $58M → $110M (+$51.6M)
16% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 19
10% more funds holding
Funds holding: 67 → 74 (+7)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$6.75M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$2.71M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$1.76M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$991K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$940K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
-$2.38M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.96M |
| 3 |
First Manhattan
New York
|
-$1.42M |
| 4 |
CI
Cowen Inc
New York
|
-$616K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$470K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HCM
76
Highlander Capital Management
Short Hills,
New Jersey
| – | -$11.4K | -1,083 | Closed |
|
77
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$920 | -56 | -88% |
|
|
GAM
78
Gemmer Asset Management
Walnut Creek,
California
| – | +$49 | +3 | New |
|
79
BlackRock
New York
| – | +$246 | +15 | New |
|
CASC Hedge Fund Activity: Q1 2014 in Review
74 of the 3,463 institutional investors tracked by Wall St. Rank reported a position in Cascadian Therapeutics, Inc. (CASC) for Q1 2014, worth a combined $110M — up 89% from $58M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new CASC positions and 7 closed out — a net gain of 8 holders — while 22 added to existing stakes and 19 trimmed.
The largest buyer was Franklin Resources, adding an estimated $6.75M. The largest seller was State of Wisconsin Investment Board, exiting entirely with an estimated $2.38M sold.
- 74 institutional investors held Cascadian Therapeutics, Inc. (CASC) as of Q1 2014, up from 67 in Q4 2013.
- Funds reported $110M of Cascadian Therapeutics, Inc. stock for Q1 2014, up 89% quarter-over-quarter.
- 15 funds opened new Cascadian Therapeutics, Inc. positions in Q1 2014 and 7 closed out, a net change of +8 holders.
- The largest Cascadian Therapeutics, Inc. buyer in Q1 2014 was Franklin Resources, an estimated $6.75M added.
- The largest Cascadian Therapeutics, Inc. seller in Q1 2014 was State of Wisconsin Investment Board, an estimated $2.38M sold.
Based on aggregated 13F filings for Q1 2014.